Leuven: The European Research Area Act is due from the Commission in 2026, and the reports reviewed for this article do not confirm whether the proposal has been tabled yet. The Commission says on its research pages that it plans to adopt the Act this year, as announced in the Competitiveness Compass, so a text could arrive in the coming weeks.

At its core, the European Research Area Act will focus on national commitments to reach a 3% R&D investment target relative to GDP, backed by new legal mechanisms. Science|Business puts the EU average at around 2.2% of GDP, which shows the distance governments must cover. The Act also aims to improve research careers, geographical and intersectoral mobility, and open science, and to protect scientific freedom, ethics and integrity.

The timetable moved forward under pressure. Science|Business reports, in an undated article, that the proposal was initially due in 2027, and Research Commissioner Ekaterina Zaharieva pushed to bring it into 2026 so the law could be finished before the end of the current political mandate. The European Research Area Act is also linked to the Choose Europe for Science agenda and to a forthcoming European Innovation Act.

Stakeholders have shown strong interest. The call for evidence in August and September 2025 drew 178 contributions from 29 countries, and the public consultation that ran from 13 October 2025 to 23 January 2026 drew 735 contributions from 50 countries. The Commission cites about two million researchers in the Union as the people the Act would serve.

Parliament has staked out a position on the European Research Area Act. Eszter Lakos of the European People’s Party drafted a report on an oral question, with a motion for a resolution, that sets four priorities. They are a separate proposal to protect freedom of scientific research, a binding framework that could take the form of a regulation, the 3% investment target written into law, and measures to remove barriers to researcher circulation through mutual recognition of qualifications and simpler visas. She aimed to adopt the resolution by March 2026, though I could not confirm that it passed.

Lakos was candid about the hardest part. Of the 3% target she said she thinks it won’t be easy because the decision lies with the member states, and she compared it with the voluntary NATO 5% commitment. That remark captures the central tension in the European Research Area Act, since the Union can set a goal but only governments control national research budgets.

Universities and research organisations will watch details more than slogans. A binding framework could rationalise overlapping instruments and tighten monitoring, but it could also add reporting duties. Whether the Act creates a real single market for researchers will depend on how it handles qualifications, visas and the portability of grants.

Three markers will show direction. The first is the publication date of the proposal, the second is whether the 3% target becomes a binding duty or a monitored aim, and the third is whether a separate academic freedom proposal follows. If the answers are firm, the European Research Area Act will give the Union a lasting legal base for research; if not, it will join a long list of well-meant targets.